DelveInsight’s “Attention-deficit/Hyperactivity Disorder Market” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Attention-deficit/Hyperactivity Disorder Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Attention-deficit/Hyperactivity Disorder market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Attention-deficit/Hyperactivity Disorder: An Overview
Attention-deficit/hyperactivity disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. It is a group of behaviors and is also called as attention deficit disorder (ADD). It is a behavioral disorder that includes symptoms such as inattentiveness, hyperactivity, and impulsiveness.
The exact cause of ADHD is still not known. Like many other illnesses, several factors can contribute to ADHD, such as genes, cigarette smoking, alcohol use, or drug use during pregnancy, exposure to environmental toxins during pregnancy, exposure to environmental toxins, such as high levels of lead, at a young age, low birth weight or brain injuries.
Attention-deficit/Hyperactivity Disorder Market Key Facts
-
Among the 7MM, the US had the highest number of cases of Attention-deficit/Hyperactivity Disorder (ADHD), followed by Japan and other European countries.
-
Among the European countries, France had the highest diagnosed prevalent population of ADHD with 2,387,100+ cases, followed by Italy in 2017. On the other hand, Germany had the lowest diagnosed prevalent population in 2017.
-
Japan was estimated to account for 3,138,300+ diagnosed prevalent cases of ADHD in 2017.
-
The Centers for Disease Control and Prevention (CDC) suggests that the estimated number of children diagnosed with ADHD, according to a national 2016 parent survey, was 1 is 6.1 million (9.4%).
-
The ADHD Institute estimates a mean worldwide prevalence of 2.2% (range: 0.1–8.1%) of ADHD in children and adolescents.
Attention-deficit/Hyperactivity Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Attention-deficit/Hyperactivity Disorder market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Attention-deficit/Hyperactivity Disorder market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Attention-deficit/Hyperactivity Disorder Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Attention-deficit/Hyperactivity Disorder (ADHD) Epidemiology Segmentation –
-
Total Diagnosed Prevalent Cases
-
Gender-specific Diagnosed Prevalent Cases
-
Gender-specific Diagnosed Prevalent Cases of ADHD in Adults
-
Subtype-specific Diagnosed Prevalent Cases
Attention-deficit/Hyperactivity Disorder Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Attention-deficit/Hyperactivity Disorder market or expected to be launched during the study period. The analysis covers Attention-deficit/Hyperactivity Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Attention-deficit/Hyperactivity Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report:
https://www.delveinsight.com/sample-request/attention-deficit-hyperactivity-disorder-adhd-market
Attention-deficit/Hyperactivity Disorder Therapeutics Analysis
Some of the key companies in the Attention-deficit/Hyperactivity Disorder (ADHD) Market include:
-
Shire
-
KemPharm
-
Tris Pharma
-
Arbor Pharma
-
Neos Therapeutics
-
Highland Therapeutics
-
Rhodes Pharmaceuticals
-
Supernus Pharmaceuticals
-
Otsuka Pharmaceuticals
-
Hisamitsu Pharmaceutical
And many others.
Attention-deficit/Hyperactivity Disorder (ADHD) Therapies covered in the report include:
-
KP415
-
KP484
-
SPN-812
-
Centanafadine
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/attention-deficit-hyperactivity-disorder-adhd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Attention-deficit/Hyperactivity Disorder Competitive Intelligence Analysis
4. Attention-deficit/Hyperactivity Disorder Market Overview at a Glance
5. Attention-deficit/Hyperactivity Disorder Disease Background and Overview
6. Attention-deficit/Hyperactivity Disorder Patient Journey
7. Attention-deficit/Hyperactivity Disorder Epidemiology and Patient Population
8. Attention-deficit/Hyperactivity Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Attention-deficit/Hyperactivity Disorder Unmet Needs
10. Key Endpoints of Attention-deficit/Hyperactivity Disorder Treatment
11. Attention-deficit/Hyperactivity Disorder Marketed Products
12. Attention-deficit/Hyperactivity Disorder Emerging Therapies
13. Attention-deficit/Hyperactivity Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Attention-deficit/Hyperactivity Disorder Market Outlook (7 major markets)
16. Attention-deficit/Hyperactivity Disorder Access and Reimbursement Overview
17. KOL Views on the Attention-deficit/Hyperactivity Disorder Market.
18. Attention-deficit/Hyperactivity Disorder Market Drivers
19. Attention-deficit/Hyperactivity Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report:
https://www.delveinsight.com/sample-request/attention-deficit-hyperactivity-disorder-adhd-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Latest Reports by DelveInsight
Polypoidal Choroidal Vasculopathy (PCV) Market
“Polypoidal Choroidal Vasculopathy Market” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Polypoidal Choroidal Vasculopathy (PCV) market size, share, and trends in the 7MM. Additionally, the report also covers the emerging therapies, key breakthroughs, latest developments, and the major companies operating in the therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/